Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK rearrange NRAS G13S |
| Therapy | Alectinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange NRAS G13S | lung non-small cell carcinoma | predicted - resistant | Alectinib | Case Reports/Case Series | Actionable | In a retrospective analysis of a Phase III trial (J-ALEX), Alecensa (alectinib) treatment demonstrated limited activity with a progression-free survival of 4.4 mo in a patient with non-small cell lung cancer harboring ALK rearrangement and NRAS G13S (PMID: 40912045). | 40912045 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40912045) | Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study. | Full reference... |